Bristol Myers Squibb has presented five-year data showing sustained reductions in cardiac obstruction and improvements in symptoms among patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) treated with Camzyos (mavacamten).
Thus, strengthening the long-term evidence base for the cardiac myosin inhibitor.
The data from the EXPLORER-LTE cohort of the MAVA-LTE study were presented as a late-breaker at the European Society of Cardiology (ESC) Congress 2026 in Munich. The study is the largest and longest evaluation to date of symptomatic oHCM patients treated with Camzyos, according to the company.
At 252 weeks, patients receiving Camzyos had a mean reduction of 38.7 mm Hg in resting left ventricular outflow tract (LVOT) gradient and a 55.6 mm Hg reduction in Valsalva LVOT gradient from the start of the long-term extension study.
Nearly all patients — 97.4% — achieved a Valsalva LVOT gradient of 30 mm Hg or less, the threshold used to define obstruction in oHCM. Meanwhile, 69.6% of patients improved by at least one New York Heart Association (NYHA) functional class, while 59.2% became asymptomatic.
“The EXPLORER-LTE data up to five years reflect the sustained and clinically meaningful effects of Camzyos for patients living with symptomatic oHCM,” said Anjali T. Owens, Medical Director of the Center for Inherited Cardiac Disease and an Associate Professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania.
“For a chronic, progressive condition that requires ongoing treatment and monitoring, long-term evidence is essential to helping clinicians better understand how a therapy may benefit patients over time.”
The long-term extension enrolled 231 patients in the United States, Europe and Israel who had completed the Phase 3 EXPLORER-HCM trial. The single-arm, open-label study was designed to assess the long-term safety and efficacy of Camzyos.
Bristol Myers Squibb said no new safety signals emerged beyond those observed in the original EXPLORER-HCM study. Mean left ventricular ejection fraction (LVEF) fell by 10.2% at 252 weeks but remained within the normal range.
The company also presented additional real-world evidence at ESC Congress, including findings from COLLIGO-HCM, a global retrospective study. According to BMS, the data showed that the effectiveness and safety profile observed with Camzyos in clinical trials was consistent in routine clinical practice, including improvements in symptoms and reductions in LVOT obstruction.
A separate observational registry study from Germany reported reductions in NYHA class consistent with previous real-world studies, while an analysis of healthcare resource utilization in Sweden highlighted the broader burden of hypertrophic cardiomyopathy and the importance of accurate diagnosis and continued care.
“For people living with symptomatic oHCM, long-term and real-world evidence provides greater confidence in treatment decisions and a clearer understanding of what sustained therapy may mean over time,” said Cristian Massacesi, executive vice president, chief medical officer and head of development, Bristol Myers Squibb.
“As part of our dedication to advancing cardiovascular research, the data presented at ESC Congress add to the understanding and trust of Camzyos and its role in helping patients manage oHCM, a serious condition affecting daily activities for many patients.”
Bristol Myers Squibb said Camzyos has the largest body of worldwide evidence among cardiac myosin inhibitors, with long-term and real-world studies extending to five years.
